Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 19/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.87 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262841 | 1.00 | KIF11 (0.87) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4262847 | 1.00 | KIF11 (0.87) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL29377772 | 0.93 | KIF11 (1.00) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL647316 | 0.93 | KIF11 (1.00) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL645543 | 0.93 | KIF11 (1.00) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL644065 | 0.92 | KIF11 (0.98) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL16354067 | 0.92 | KIF11 (0.98) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL649759 | 0.92 | KIF11 (0.98) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL644223 | 0.92 | KIF11 (0.97) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| Sb-743921 SCHEMBL362802 | 0.92 | KIF11 (0.97) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491746-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | KIF11 525/4885KCNH2 3954/4885MAP1LC3B 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.